Medigen Biotechnology Corp. (TPEX:3176)
Taiwan · Delayed Price · Currency is TWD 32.70
-0.40 (-1.21%)
May 29, 2026, 1:30 PM CST
Medigen Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -264.4 | -108.8 | -204.69 | -561.3 | -675.87 | -52.61 |
Depreciation & Amortization | 176.01 | 172.89 | 172.31 | 175.77 | 189.13 | 196.35 |
Other Amortization | 2.89 | 2.89 | 14.1 | 32.87 | 21.87 | 2.08 |
Loss (Gain) From Sale of Assets | 10.83 | 9.06 | -69.27 | 1.03 | - | 0.25 |
Loss (Gain) From Sale of Investments | -1.39 | -0.04 | -1.44 | 9.58 | 16.66 | -10.92 |
Loss (Gain) on Equity Investments | 47.07 | 43.08 | 28.44 | 92.26 | 262.21 | 98.8 |
Stock-Based Compensation | 39.49 | 31.01 | - | 22.37 | 82.07 | 77.4 |
Provision & Write-off of Bad Debts | 5.17 | 4.67 | 6.48 | 14.44 | 21.13 | -20.49 |
Other Operating Activities | -88.2 | -55.59 | 86.5 | -800.48 | -1,220 | 1,181 |
Change in Accounts Receivable | 39.2 | -0.9 | 13.86 | 43.35 | 443.69 | -650.83 |
Change in Inventory | 24.71 | 63.79 | -97.83 | 145.92 | 60.29 | -429.02 |
Change in Accounts Payable | -5.74 | -18.21 | -0.61 | -74.37 | 30.8 | 53.83 |
Change in Unearned Revenue | 5.04 | -71.09 | 95.37 | 4.6 | -114.03 | 130.5 |
Change in Other Net Operating Assets | -13.12 | -32.21 | -5.3 | 336.49 | -255.21 | -58.37 |
Operating Cash Flow | -22.46 | 40.55 | 37.92 | -503.52 | -1,138 | 518.12 |
Operating Cash Flow Growth | - | 6.93% | - | - | - | - |
Capital Expenditures | -165.25 | -71.45 | -54.85 | -38.41 | -148.16 | -142.96 |
Sale of Property, Plant & Equipment | 17.7 | 17.7 | 156.87 | - | - | 126 |
Sale (Purchase) of Intangibles | -1.18 | -1.96 | -2.17 | -3.49 | -3.21 | -1.59 |
Investment in Securities | -253.51 | -8.02 | 802.02 | 492.47 | -2,297 | -879.7 |
Other Investing Activities | -242.09 | -2.91 | 1.42 | 47.09 | -4.54 | -12.25 |
Investing Cash Flow | -644.34 | -66.63 | 903.3 | 497.66 | -2,453 | -910.5 |
Short-Term Debt Issued | - | 164.2 | 118.9 | 210 | 308 | 370 |
Long-Term Debt Issued | - | 30 | 67.5 | 29.7 | 1,755 | - |
Total Debt Issued | 877.3 | 194.2 | 186.4 | 239.7 | 2,063 | 370 |
Short-Term Debt Repaid | - | -224.4 | -291.7 | -135.4 | -280 | -545 |
Long-Term Debt Repaid | - | -60.62 | -1,847 | -28.23 | -28.91 | -22.49 |
Total Debt Repaid | -171.93 | -285.02 | -2,139 | -163.63 | -308.91 | -567.49 |
Net Debt Issued (Repaid) | 705.37 | -90.82 | -1,952 | 76.07 | 1,754 | -197.49 |
Issuance of Common Stock | - | - | 3.4 | 3.29 | 2.41 | 11.27 |
Repurchase of Common Stock | - | - | - | -18.59 | - | - |
Other Financing Activities | 47.61 | 53.01 | 175.61 | 132.39 | 1,734 | 517.57 |
Financing Cash Flow | 752.98 | -37.8 | -1,773 | 193.15 | 3,490 | 331.35 |
Foreign Exchange Rate Adjustments | 2.27 | -0.23 | -3.26 | -5 | -3.08 | -0.96 |
Net Cash Flow | 88.46 | -64.12 | -835.21 | 182.29 | -103.95 | -62 |
Free Cash Flow | -187.71 | -30.9 | -16.93 | -541.93 | -1,286 | 375.16 |
Free Cash Flow Margin | -13.96% | -1.95% | -1.23% | -46.81% | -121.82% | 9.57% |
Free Cash Flow Per Share | -1.34 | -0.22 | -0.12 | -3.89 | -9.25 | 2.70 |
Cash Interest Paid | 22.98 | 22.98 | 25.22 | 25.61 | 20.1 | 19.07 |
Cash Income Tax Paid | 26.96 | 26.96 | 56.06 | 40.23 | 23.35 | 8.37 |
Levered Free Cash Flow | -94.22 | 9.11 | 12.53 | -190.22 | -660.21 | -246.5 |
Unlevered Free Cash Flow | -79.48 | 23.42 | 24.1 | -185.56 | -654.91 | -234.58 |
Change in Working Capital | 50.08 | -58.62 | 5.49 | 509.94 | 164.71 | -953.32 |